ReviewPathologica2021
Cholangiocarcinoma.
Review in Pathologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 3 syntheses or guidelines pooled it, 185 citations in OpenAlex.
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer.ESMO open · 2024Guideline
- Role of long non-coding RNAs in cholangiocarcinoma: A systematic review and meta-analysis.Cancer reports (Hoboken, N.J.) · 2024Pooled it
- Prevalence and predictive value of sarcopenia in surgically treated cholangiocarcinoma: a comprehensive review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Review
- Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study.ESMO gastrointestinal oncology · 2026Article
- Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy.Yonsei medical journal · 2026Article
- Review
- Self-Supervised Transformer-Based Pipeline for Liver Tumor Segmentation and Type Classification.JCO clinical cancer informatics · 2026Article
- UCHL1 Maintains MUC3A Stability through Deubiquitination to Activate the Downstream Pathways of EGFR, Driving Proliferation and Epithelial-Mesenchymal Transition in Extrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Article
- Article
- Integrin αvβ3 is a Potential Therapeutic Target in Cholangiocarcinoma.International journal of medical sciences · 2026Article
- Case Report: Intrahepatic cholangiocarcinoma masquerading as a giant hepatic cyst.Frontiers in oncology · 2026Article
- Exosomes and cholangiocarcinoma: mechanisms, diagnostic, and therapeutic perspectives.Frontiers in immunology · 2026Review
- Exploratory study on the role of Clonorchis sinensis infection in promoting cholangiocarcinoma progression.Parasites & vectors · 2025Article
- Harmonization trial ofPathologica · 2025Article
- Second-Line Treatment in cholangiocarcinoma - Current State of the Art and Future Perspectives.Current treatment options in oncology · 2025Review
- Wuweizisu B for cancer treatment from multitarget mechanisms to precision delivery strategies (Review).International journal of molecular medicine · 2025Review
- Construction and validation of gene signature for prognosis and drug sensitivity in cholangiocarcinoma based on cellular senescence related genes.Scientific reports · 2025Article
- Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1.International journal of molecular sciences · 2025Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cancer represents the third leading cause of cancer-related death worldwide. Cholangiocarcinoma (CCA) is the second most common type of liver cancer after hepatocellular carcinoma, accounting for 10-15% of all primary liver malignancies. Both the incidence and mortality of CCA have been steadily increasing during the last decade. Moreover, most CCAs are diagnosed at an advanced stage, when therapeutic options are very limited. CCA may arise from any tract of the biliary system and it is classified into intrahepatic, perihilar, and distal CCA, according to the anatomical site of origin. This topographical classification also reflects distinct genetic and histological features, risk factors, and clinical outcomes. This review focuses on histopathology of CCA, its differential diagnoses, and its diagnostic pitfalls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.